MedPath

Mechanisms Underlying Postoperative Insulin Resistance and Inflammation

Phase 4
Conditions
Obesity
Interventions
Dietary Supplement: carbohydrate drink
Procedure: Muscle biopsy
Procedure: Blood sampling
Dietary Supplement: Placebo
Registration Number
NCT01470534
Lead Sponsor
University of Nottingham
Brief Summary

Having an operation places an enormous burden on the body, leading to the development of inflammation and so called 'insulin resistance'. Insulin resistance means the body is unable to respond to important hormones that control use of energy. Recent studies have shown that patients who develop 'higher' insulin resistance and inflammation have more serious complications and take longer to recover after surgery. The investigators do not know what controls the development of insulin resistance and inflammation after surgery. Similarly, the investigators do not know why certain patients develop much more insulin resistance and inflammation than others, even though they have the same operation.

The main purpose of the study is to try to find out which patients are prone to developing greater 'amounts' of insulin resistance and inflammation. The investigators also want to find out whether the investigators can reduce the 'amount' of insulin resistance and inflammation in these patients (for example by giving them carbohydrate \[sugar-based\] drinks before surgery - these have been shown to reduce insulin resistance in some patient groups).

Information from this study should improve the way the investigators prepare patients before surgery and this should help to improve patient outcomes following surgery (by reducing complications and speeding recovery after major surgery).

Detailed Description

Interested participants who are undergoing abdominal (tummy) surgery will be recruited from surgical clinics. They will be asked to attend the Greenfield Human Physiology Laboratory where they will be asked to complete two questionnaires. In addition, a sample of blood, and a small sample of muscle and fat from their thigh will be taken. They will undergo a low dose X-ray (DXA scan) and an insulin clamp. The insulin clamp involves being connected to an insulin and glucose drip for around four hours during which their blood pressure and pulse is monitored and regular blood samples are taken.

Participants will be allocated randomly to one of two groups. One group will receive a carbohydrate (sugar) drink before surgery and the other group will receive a dummy (placebo) drink.

On the day of surgery, pre-operative checks and assessment will proceed as normal. After the participant is asleep under anaesthetic, a blood sample and tummy muscle and fat samples will be taken by the surgeon through the surgical incision. At the end of surgery, another blood sample and muscle and fat samples from the tummy and thigh will be taken while the participant is still under anaesthetic.

On the day after surgery, a further blood test and tummy and thigh muscle and fat sample will be taken. Participants will also undergo another insulin clamp.

The research team will follow participants' progress after surgery, but the decision to allow them home will be made by the medical team responsible for their care.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Age 18-75 yrs
  • Correct BMI and waist circumference criteria : Obese group - BMI ≥30 AND waist circumference ≥94 cm in men and ≥ 80 cm in women, Non obese group - BMI 18.5-25 AND waist circumference ≤94cm in men and ≤80 cm in women Due to undergo elective major abdominal surgery ASA I-III Caucasian patients Able to give informed consent and comply with study protocol
Exclusion Criteria
  • History of significant preoperative weight loss (>10% over preceding 3 weeks)

    • Clinical history of pulmonary aspiration
    • Known gastro-oesophageal reflux disease (GORD) or hiatus hernia
    • History of difficult intubation or conditions leading to the latter such as: previous neck radiotherapy/rheumatoid arthritis/presence of thyroid goitre
    • Metabolic disorders (e.g. diabetes mellitus, thyroid disease, Cushing's Syndrome)
    • Simultaneous participation in another clinical study or involvement in a clinical study within the preceding 3 months,
    • Patients with suspicion of alcohol/drug abuse
    • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Normal body weightcarbohydrate drink-
Normal body weightMuscle biopsy-
Normal body weightBlood sampling-
Obesecarbohydrate drink-
ObeseMuscle biopsy-
ObeseBlood sampling-
Normal Body Weight placeboMuscle biopsyParticipants of mormal body weight given placebo
Normal Body Weight placeboBlood samplingParticipants of mormal body weight given placebo
Normal Body Weight placeboPlaceboParticipants of mormal body weight given placebo
Obese placeboMuscle biopsyParticipants who are obese given placebo
Obese placeboBlood samplingParticipants who are obese given placebo
Obese placeboPlaceboParticipants who are obese given placebo
Primary Outcome Measures
NameTimeMethod
Within subject differences in perioperative insulin sensitivity (M-value, corrected for insulin concentrations) amongst obese, non-obese, carbohydrate loaded and non-carbohydrate loaded patients.2 weeks
Secondary Outcome Measures
NameTimeMethod
Correlation between body composition and changes in perioperative insulin sensitivity2 weeks
Differences in inflammatory cytokine gene expression2 months
Differences in muscle and fat genes and proteins controlling carbohydrate/fat oxidation and insulin signalling3 months
Differences activities of muscle and fat enzymes involved in carbohydrate/fat/carnitine metabolism2 months
Differences in the aforementioned between peripheral and central fat and muscle2 months
The incidence of post-operative infectious and non-infectious complications30 days
Length of hospital stay (difference between groups)6 weeks

Trial Locations

Locations (1)

University of Nottingham

🇬🇧

Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath